Compare BIO & CIGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIO | CIGI |
|---|---|---|
| Founded | 1952 | 1972 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.3B |
| IPO Year | N/A | N/A |
| Metric | BIO | CIGI |
|---|---|---|
| Price | $319.48 | $143.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $358.50 | $175.00 |
| AVG Volume (30 Days) | ★ 156.6K | 121.5K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 0.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.30 |
| Revenue | $2,557,500,000.00 | ★ $5,453,534,000.00 |
| Revenue This Year | $1.89 | $17.67 |
| Revenue Next Year | $2.45 | $7.35 |
| P/E Ratio | ★ N/A | $63.08 |
| Revenue Growth | N/A | ★ 19.71 |
| 52 Week Low | $211.43 | $100.86 |
| 52 Week High | $373.69 | $171.51 |
| Indicator | BIO | CIGI |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 42.32 |
| Support Level | $298.35 | $141.94 |
| Resistance Level | $328.07 | $145.75 |
| Average True Range (ATR) | 10.38 | 3.23 |
| MACD | 0.29 | 0.58 |
| Stochastic Oscillator | 60.79 | 47.52 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are; Real Estate Services, Engineering, Investment Management, and Corporate. Maximum revenue for the company is generated from its Real Estate Services segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, property sales brokerage, and lease brokerage services, among others. Geographically, the company generates maximum revenue from the United States and the rest from Canada, Australia, the United Kingdom, Poland, China, India, and other regions.